Icatibant Fresenius (Icatibant Acetate)

• Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema, a rare genetic disorder characterized by recurrent, potentially life‑threatening attacks of edema.
• Acute hereditary angioedema (C1‑inhibitor deficiency, type I): provides rapid reduction of subcutaneous and submucosal swelling, helping restore normal breathing and reduce pain.
• Acute hereditary angioedema (C1‑inhibitor deficiency, type II): quickly reverses edema of the lips, tongue, and airway, decreasing risk of life‑threatening obstruction.
• Hereditary angioedema with normal C1‑inhibitor (HAE‑nC1‑INH): alleviates attack‑related swelling when bradykinin‑mediated, offering symptom control.
• Hereditary angioedema attacks involving the gastrointestinal tract: reduces abdominal pain and vomiting associated with edema.

• Icatibant acetate selectively binds to the bradykinin B2 receptor on vascular endothelial cells, acting as a competitive antagonist. By blocking the receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are responsible for the rapid swelling seen in hereditary angioedema attacks. The inhibition of this pathway restores normal vascular tone and reduces fluid extravasation, leading to prompt resolution of edema.

Icatibant may cause a range of adverse reactions, most of which are related to its subcutaneous administration.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Redness: localized erythema around the injection area.
• Swelling: transient edema at the site of administration.
• Nausea: occasional feeling of nausea without vomiting.
• Headache: mild to moderate headache episodes.
• Dizziness: brief sensations of light‑headedness.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Angioedema: unexpected swelling of face, lips, or airway.
• Hypotension: sudden drop in blood pressure, potentially causing faintness.
• Severe injection site necrosis: tissue death at injection site.
• Thrombocytopenia: low platelet count observed in rare cases.

When using Icatibant, healthcare professionals should observe specific precautions to ensure patient safety.

• Monitor for hypersensitivity: watch for signs of allergic reaction after each injection.
• Use under medical supervision: administration should be performed by trained personnel.
• Not for prophylaxis: the drug is intended only for acute attack treatment, not routine prevention.
• Caution in cardiovascular disease: assess blood pressure and cardiac status before use.
• Pregnancy and lactation: avoid unless benefits outweigh potential risks, as safety data are limited.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence the bradykinin system or affect injection site reactions.

Major Interactions (Avoid)

• ACE inhibitors: may increase bradykinin levels and reduce Icatibant efficacy.
• Neprilysin inhibitors: can elevate bradykinin, potentially diminishing therapeutic effect.
• Estrogen‑containing therapies: may exacerbate angioedema and interfere with treatment.
• C1‑inhibitor concentrate therapy: simultaneous use may complicate assessment of response.

Moderate Interactions (Monitor Closely)

• NSAIDs: may increase risk of local inflammation at injection site.
• Antihistamines: concurrent use may mask early signs of hypersensitivity.
• Other subcutaneous biologics: monitor for cumulative injection site reactions.
• Corticosteroids: may alter inflammatory response, monitor edema resolution.